Prevalence of Uncontrolled Hypertension in Patients With Fabry Disease

American Journal of Hypertension

Volumn 19, Issue 8, 2006, Pages 782-787

  Kleinert, Julia ^a   Dehout, François ^b   Schwarting, Andreas ^c   de Lorenzo, Abelardo García ^d   Ricci, Roberta ^e   Kampmann, Christoph ^c   Beck, Michael ^c   Ramaswami, Uma ^f   Linhart, Ales ^g   Gal, Andreas ^h   Houge, Gunnar ⁱ   Widmer, Urs ^j   Mehta, Atul ^k   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Centre Hospitalier Universitaire de Charleroi   (Belgium)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g CHARLES UNIVERSITY   (Czech Republic)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF ZURICH   (Switzerland)

^k ROYAL FREE HOSPITAL   (United Kingdom)

more..

Author keywords

Blood pressure; Fabry disease; glomerular filtration rate; hypertension; reno protection

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHILD; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIALYSIS; FABRY DISEASE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY TRANSPLANTATION; MALE; PREVALENCE; SEX RATIO;

EID: 33746318436     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.01.011     Document Type: Article

References (21)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., and Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276 (1967) 1163-1167
2. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., and Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder. expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138 (2003) 338-346
3. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease. clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38 (2001) 769-775
4. Whybra C., Kampmann C., Willers I., Davies J., Winchester B., Kriegsmann J., Bruhl K., Gal A., Bunge S., and Beck M. Anderson-Fabry disease. clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24 (2001) 715-724
5. Alroy J., Sabnis S., and Kopp J.B. Renal pathology in Fabry disease. J Am Soc Nephrol 13 Suppl 2 (2002) S134-S138
6. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., Jones D.W., Materson B.J., Oparil S., Wright Jr. J.T., and Roccella E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. the JNC 7 report. J Am Med Assoc 289 (2003) 2560-2572
7. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 Suppl 1 (2004) S65-S230
8. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21 (2003) 1011-1053
9. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., and Beck M. Fabry disease defined. baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34 (2004) 236-242
10. Levey A.S. Clinical practice. Nondiabetic kidney disease. N Engl J Med 347 (2002) 1505-1511
11. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 Suppl 2 (2002) S1-S246
12. Lewington S., Clark R., Qizilbash N., Peto R., and Collins R. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 360 (2002) 1903-1913
13. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., Shulman N.B., and Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med 334 (1996) 13-18
14. Wolf-Maier K., Cooper R.S., Banegas J.R., Giampaoli S., Hense H.W., Joffres M., Kastarinen M., Poulter N., Primatesta P., Rodriguez-Artalejo F., Stegmayr B., Thamm M., Tuomilehto J., Vanuzzo D., and Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Assoc 289 (2003) 2363-2369
15. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease. clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38 (2001) 750-760
16. Thadhani R., Wolf M., West M.L., Tonelli M., Ruthazer R., Pastores G.M., and Obrador G.T. Patients with Fabry disease undergoing dialysis in the United States. Kidney Int 61 (2002) 249-255
17. Branton M.H., Schiffmann R., Sabnis S.G., Murray G.J., Quirk J.M., Altarescu G., Goldfarb L., Brady R.O., Balow J.E., Austin Iii H.A., and Kopp J.B. Natural history of Fabry renal disease. influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81 (2002) 122-138
18. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
19. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. Enzyme replacement therapy in Fabry disease. a randomized controlled trial. J Am Med Assoc 285 (2001) 2743-2749
20. Beck M., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Houge G., Ramaswami U., Gal A., and Mehta A. Fabry disease. overall effects of agalsidase treatment. Eur J Clin Invest 34 (2004) 838-844
21. Wilcox W.R., Banikazemi M., Guffon N., Waldek S., Lee P., Linthorst G.E., Desnick R.J., and Germain D.P. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75 (2004) 65-74